NCT01756404 is a Phase 1 clinical trial of Canagliflozin (JNJ-28431754) in Healthy, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..

Who is sponsoring NCT01756404?

NCT01756404 is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..

What drugs are being tested in NCT01756404?

Interventions in NCT01756404: Canagliflozin (JNJ-28431754), Placebo.

Is NCT01756404 still recruiting?

NCT01756404 is currently completed. Last updated 13 December 2018.

Last reviewed 2018-12-13 · How we verify

NCT01756404

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

Completed Phase 1 Last updated 13 December 2018

What this trial tests

Phase 1 trial testing Canagliflozin (JNJ-28431754) in Healthy in 80 participants. Completed in 5 December 2007.

Timeline

14 June 2007

Primary endpoint
5 December 2007

5 December 2007

Quick facts

Lead sponsor	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	double
Primary purpose	treatment
Enrollment	80
Start date	14 June 2007
Primary completion	5 December 2007
Estimated completion	5 December 2007
Sites	1 location across United States

Drugs / interventions tested

Canagliflozin (JNJ-28431754) — full drug profile →
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. — full company profile →

Who can join

Adults 18 to 60, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the pharmacokinetics (ie, how the body affects the drug) and pharmacodynamics (ie, how the drug affects the body) of increasing doses of canagliflozin (JNJ-28431754) in healthy obese volunteers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity.
Pereira MJ, Eriksson JW. · · 2019 · cited 231× · PMID 30701480 · DOI 10.1007/s40265-019-1057-0

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Johnson & Johnson Pharmaceutical Research & Development, L.L.C. trials

Trials by the same sponsor.

NCT04330248 — A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants · Phase 1 · completed
NCT01094262 — A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthrit · Phase 2 · terminated
NCT01060254 — A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain · Phase 2 · terminated
NCT00973141 — A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis · Phase 2 · terminated
NCT01217697 — Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer · approved for marketing

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01756404 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Last refreshed: 13 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01756404.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing